PharmaCyte Biotech Inc
PMCBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 1:41 PM ET
0.3922-0.0099 (-2.46%)
2026-11-11 19:42 CET
Market cap
4.32 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-20.63 USD m
Free cash flow, TTM
-3.94 USD m
EPS diluted, TTM
-2.40
P/E
-
Price
PMCB against its 20, 50 and 200-day averages2050200
74.0% under the 52-week high of 1.51 on 5 Dec 2025. 52-week low 0.25 on 11 Nov 2026. Last 15 sessions, 73.2% high to low
Profile
PMCB52-week range, 8% of the way up
0.301.51
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.
| Employees | 2 |
|---|---|
| IPO | Sep 11, 2003 |
| Beta | 0.72 |
| ATR, 14d | 0.05 |
| Rel volume | 8.54 |
| Short float | 0.50% |
| Insider own | 6.21% |
| Inst own | 7.47% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 4.21M |
| Enterprise Value | -24.41M |
| Income | -20.63M |
| Sales | 0.00M |
| Book/sh | 2.56 |
| Cash/sh | 2.84 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 2 |
| IPO | Sep 11, 2003 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 0.15 |
| P/C | 0.14 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 40.30 |
| Current Ratio | 40.30 |
| Debt/Eq | 0.00 |
| LT Debt/Eq | 0.00 |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | -2.40 |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | -132.11% -2.40% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | -422.63% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 56.19% |
| Sales Q/Q | - |
| Earnings | - |
| EPS/Sales Surpr. | - - |
Ownership
| Insider Own | 6.21% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 7.47% |
| Inst Trans | -3.11% |
| ROA | -39.47% |
| ROE | -44.24% |
| ROIC | -54.92% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | 11.04% |
| SMA50 | -1.12% |
| SMA200 | -37.02% |
| Trades | - |
Technical
| Shs Outstand | 10.74M |
|---|---|
| Shs Float | 10.07M |
| Short Float | 0.50% |
| Short Ratio | 0.26 |
| Short Interest | 0.05M |
| 52W High | 1.51 -74.03% |
| 52W Low | 0.30 29.82% |
| Volatility | 16.11% 11.29% |
| ATR (14) | 0.05 |
| RSI (14) | 54.57 |
| Beta | 0.72 |
| Rel Volume | 8.54 |
| Avg Volume | 196.06K |
| Volume | 1,111,073 |
Performance
| Perf Week | 2.94% |
|---|---|
| Perf Month | 10.20% |
| Perf Quarter | -28.69% |
| Perf Half Y | -51.70% |
| Perf YTD | -45.83% |
| Perf Year | -55.33% |
| Perf 3Y | -81.93% |
| Perf 5Y | -85.89% |
| Perf 10Y | -99.08% |
| Recom | - |
| Target Price | - |
| Prev Close | 0.40 |
| Price | 0.39 |
| Change % | -2.46% |
Peers
Mkt capInsider trading
6 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Silverman Joshua | CEO and President | Jan 07 '26 | Buy | 0.83 | 40,000 | 33,316 | 416,250 | Jan 07 05:43 PM |
| Silverman Joshua | CEO and President | Jan 06 '26 | Buy | 0.79 | 30,000 | 23,667 | 376,250 | Jan 07 05:43 PM |
| Silverman Joshua | CEO and President | Jan 05 '26 | Buy | 0.78 | 30,000 | 23,493 | 346,250 | Jan 07 05:43 PM |
| SCHECHTER JONATHAN | Director | Jan 07 '26 | Buy | 0.84 | 20,000 | 16,872 | 192,500 | Jan 07 05:43 PM |
| SCHECHTER JONATHAN | Director | Jan 06 '26 | Buy | 0.79 | 20,000 | 15,808 | 172,500 | Jan 07 05:43 PM |
| SCHECHTER JONATHAN | Director | Jan 05 '26 | Buy | 0.78 | 20,000 | 15,552 | 152,500 | Jan 07 05:43 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
News
latest 14 of 68- PharmaCyte Biotech, Inc. Announces Reverse Stock Split (Business Wire)
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment (Business Wire) +36.92%
- PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications (Business Wire)
- PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing (Business Wire) -7.22%
- PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors (Business Wire) +12.23%
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease (Business Wire)
- PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024 (InvestorPlace) +6.47%
- PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024 (InvestorPlace)
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Womens Health Innovator Femasys, Inc. (Business Wire)
- Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech (GlobeNewswire)
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology (Business Wire)
- PharmaCyte Biotech Announces Final Results of Tender Offer (Business Wire)
- PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share (Business Wire) +12.77%
- PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan (Business Wire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2021Q4 | 2022-06-29 | -0.070 | - | -0.895 | 0.00 | - | - |
| 2021Q3 | 2022-03-15 | -0.040 | -0.050 | -0.037 | 0.00 | 0.00 | 1 |
| 2021Q2 | 2021-12-15 | -0.060 | -0.060 | -0.056 | 0.00 | 0.00 | 1 |
| 2021Q1 | 2021-11-05 | -0.640 | - | -0.644 | 0.00 | - | - |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2014FY | -30.000 | -30.000 | -30.000 | - | - |
| 2021FY | -0.270 | - | -0.273 | 0.00 | - |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| No estimate revisions. | ||||||||
Estimate history
| EPS, annual | -15 | -5.55 | -4.23 | -2.46 | -0.273 | -0.222 | -1.799 | 3.187 | -2.77 | -2.3994 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | 1.901 | -0.387 | -0.438 | 1.596 | -1.23 | -1.239 | -0.168 | -0.454 | -0.539 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
| Shares, annual | 0.676 | 0.791 | 1.092 | 1.589 | 1.59 | 16.794 | 8.038 | 6.796 | 10.736 | 10.736 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 7.717 | 7.034 | 6.905 | 6.796 | 6.796 | 6.796 | 10.736 | 10.736 | 10.736 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 5.46 | 5.30 | 4.38 | 6.52 | 6.46 | 4.39 | 3.62 | 3.83 | 4.10 |
| Research and Development | 0.36 | 0.39 | 0.44 | 0.41 | 0.47 | 0.69 | 0.92 | 0.30 | 0.46 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.46 | -5.30 | -4.38 | -6.52 | -6.46 | -4.39 | -3.62 | -3.83 | -4.10 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 13.86 | 17.11 | -12.22 | -4.84 | 0.00 | 0.00 | -0.08 | 0.00 | - |
| Net Income Before Taxes | -16.15 | -19.42 | 30.66 | 0.33 | -4.32 | -4.24 | -3.55 | -3.83 | -4.07 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -16.15 | -19.42 | 30.66 | 0.33 | -4.32 | -4.24 | -3.55 | -3.83 | -4.07 |
| Net Income From Continuing Operations | -16.15 | -19.42 | 30.66 | 0.33 | -4.32 | -4.24 | -3.55 | -3.83 | -4.07 |
| Net Income | -20.63 | -23.21 | 23.36 | -17.24 | -4.32 | -4.24 | -3.55 | -3.83 | -4.07 |
| EPS (Recurring) | -1.02 | -1.34 | 2.02 | -2.15 | -0.22 | -0.27 | -2.49 | -4.23 | -5.55 |
| EPS (Basic, Before Extraordinaries) | -2.40 | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 | -2.46 | -4.23 | -5.55 |
| EPS (Diluted) | -2.40 | -2.77 | 3.19 | -1.80 | -0.22 | -0.27 | -2.46 | -4.23 | -5.55 |
| EBITDA | -5.46 | -5.30 | -4.38 | -6.52 | -6.46 | -4.39 | -3.62 | -3.83 | -4.10 |
| Non-Operating Income (Expense) | 3.18 | 2.99 | 22.81 | 2.02 | 2.14 | 0.15 | -0.00 | -4E-05 | 0.03 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.18 | 0.24 | 0.48 | 1.32 | 1.23 | 1.54 | 0.37 | 1.59 | 1.56 |
| Price To Earnings Ratio | - | - | 1.63 | - | - | - | - | - | - |
| Shares Outstanding | 10.74 | 10.74 | 6.80 | 8.04 | 16.79 | 1.59 | 1.59 | 1.09 | 0.79 |
| Market Capitalization | 4.32 | 4.32 | 8.51 | 17.95 | 50.93 | 48.28 | 42.23 | 40.15 | 48.63 |
Income statement, quarterly
| Metric | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 1.01 | 0.96 | 2.12 | 1.38 | 0.85 | 1.04 | 0.96 | 1.11 |
| Research and Development | 0.06 | 0.06 | 0.09 | 0.14 | 0.10 | 0.13 | 0.12 | 0.10 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -1.01 | -0.96 | -2.12 | -1.38 | -0.85 | -1.04 | -0.96 | -1.11 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 4.48 | 5.13 | -2.63 | 6.89 | 7.73 | -12.56 | 2.34 | 0.74 |
| Net Income Before Taxes | -5.08 | -4.39 | 0.75 | -7.42 | -8.36 | 11.75 | -3.05 | -1.47 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -5.08 | -4.39 | 0.75 | -7.42 | -8.36 | 11.75 | -3.05 | -1.47 |
| Net Income From Continuing Operations | -5.08 | -4.39 | 0.75 | -7.42 | -8.36 | 11.75 | -3.05 | -1.47 |
| Net Income | -5.79 | -4.87 | -1.56 | -8.42 | -8.36 | 10.85 | -3.05 | -2.96 |
| EPS (Recurring) | -0.25 | -0.12 | -0.37 | -0.53 | -0.43 | 0.30 | -0.20 | -0.32 |
| EPS (Basic, Before Extraordinaries) | -0.54 | -0.45 | -0.17 | -1.24 | -1.23 | 1.60 | -0.44 | -0.39 |
| EPS (Diluted) | -0.54 | -0.45 | -0.17 | -1.24 | -1.23 | 1.60 | -0.44 | -0.39 |
| EBITDA | -1.01 | -0.96 | -2.12 | -1.38 | -0.85 | -1.04 | -0.96 | -1.11 |
| Non-Operating Income (Expense) | 0.41 | 1.69 | 0.23 | 0.85 | 0.22 | 0.23 | 0.26 | 0.38 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.00 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | 0.12 |
| Price To Earnings Ratio | - | - | - | - | 1.34 | 1.63 | 2.94 | 2.68 |
| Shares Outstanding | 10.74 | 10.74 | 10.74 | 6.80 | 6.80 | 6.80 | 6.90 | 7.03 |
| Market Capitalization | 4.32 | 7.75 | 8.30 | 6.32 | 7.00 | 8.51 | 11.18 | 13.90 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 37.08 | 15.54 | 50.18 | 68.04 | 85.40 | 2.20 | 0.89 | 0.52 | 1.06 |
| Short Term Receivables | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.10 | 6.84 | 0.26 | 0.11 | 0.09 | 0.07 | 0.14 | 0.14 | 0.22 |
| Total Current Assets | 37.42 | 22.38 | 50.44 | 68.15 | 85.49 | 2.28 | 1.04 | 0.65 | 1.28 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 9.32 | 31.24 | 7.91 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 | 1.57 |
| Intangible Assets | 0.00 | 1.55 | 1.55 | 3.55 | 3.55 | 3.55 | 3.55 | 3.55 | 3.55 |
| Other Assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Total Assets | 46.75 | 55.17 | 59.90 | 73.28 | 90.62 | 7.40 | 6.17 | 5.78 | 6.41 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.03 | 0.00 | 0.00 |
| Accounts Payable | 0.27 | 0.40 | 0.39 | 0.13 | 0.21 | 0.17 | 0.19 | 0.12 | 0.35 |
| Other Current Liabilities | 0.56 | 2.52 | 7.03 | 0.46 | 0.50 | 0.50 | 0.82 | 0.62 | 0.29 |
| Total Current Liabilities | 0.83 | 2.91 | 7.42 | 0.59 | 0.70 | 0.72 | 1.03 | 0.74 | 0.64 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 10.95 | 0.36 | 12.97 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 11.77 | 3.28 | 20.39 | 0.59 | 0.70 | 0.72 | 1.08 | 0.74 | 0.64 |
| Non-Equity Reserves | 0.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 1.27 | 0.00 | 11.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 33.29 | 51.89 | 27.65 | 72.69 | 89.92 | 6.68 | 5.09 | 5.04 | 5.77 |
| Total Shareholders Equity | 34.56 | 51.89 | 39.51 | 72.69 | 89.92 | 6.68 | 5.09 | 5.04 | 5.77 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 34.56 | 51.89 | 39.51 | 72.69 | 89.92 | 6.68 | 5.09 | 5.04 | 5.77 |
| Total Liabilities & Stockholders Equity | 46.75 | 55.17 | 59.90 | 73.28 | 90.62 | 7.40 | 6.17 | 5.78 | 6.41 |
| Book Value Per Share | 3.10 | 7.64 | 3.44 | 4.33 | 56.55 | 4.20 | 4.66 | 6.37 | 8.54 |
| Tangible Book Value Per Share | 3.10 | 7.41 | 3.25 | 4.12 | 54.32 | 1.97 | 1.41 | 1.88 | 3.29 |
| Full-Time Employees | 2 | 2 | 2 | 2 | 27 | 16 | 15 | 12 | 9 |
| Price to Book Ratio | 0.16 | 0.21 | 0.62 | 0.69 | 0.53 | 6.32 | 7.89 | 9.65 | 9.48 |
| Return on Assets | -38.12 | 53.28 | 0.50 | -5.27 | -8.65 | -52.34 | -64.05 | -66.70 | -90.57 |
| Return on Equity | -44.94 | 67.08 | 0.59 | -5.31 | -8.78 | -60.35 | -75.57 | -75.26 | -98.57 |
| Return on Invested Capital | -56.20 | 59.08 | 0.84 | -5.94 | -4.71 | -53.17 | -74.52 | -80.71 | -118.38 |
| Quick Ratio | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 | 3.14 | 1.01 | 0.88 | 1.99 |
| Current Ratio | 45.28 | 7.68 | 6.80 | 116.18 | 121.38 | 3.14 | 1.01 | 0.88 | 1.99 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -23.71 | -26.99 | 30.66 | 0.33 | -4.32 | -4.24 | -3.55 | -3.83 | -4.07 |
| Other Funds (Non Cash) | 20.92 | 23.76 | -34.99 | -2.78 | 0.82 | 0.11 | 0.37 | 1.22 | 1.02 |
| Funds from Operations | -2.79 | -3.23 | -4.33 | -2.45 | -3.50 | -4.13 | -3.19 | -2.61 | -3.05 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -1.15 | -1.93 | 1.36 | 0.30 | -0.30 | 0.01 | -0.15 | 0.27 | 0.17 |
| Cash from Operating Activities | -3.94 | -5.15 | -2.98 | -2.15 | -3.79 | -4.12 | -3.33 | -2.34 | -2.88 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 2.00 | 2.00 | -7.00 | -5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | -3.00 | -3.00 | -7.00 | -5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 5.00 | 5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 2.00 | 2.00 | -7.00 | -5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | -0.33 | -0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 6.83 | 6.83 | -25.03 | -10.71 | -13.56 | 87.36 | 4.70 | 2.66 | 2.34 |
| Repurchase of Common Pref Stock | -0.40 | -0.40 | -25.03 | -44.36 | -13.56 | 0.00 | 0.00 | -1E-06 | 0.00 |
| Sale of Common Pref Stock | 7.23 | 7.23 | 0.00 | 33.65 | 0.00 | 87.36 | 4.70 | 2.66 | 2.34 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 33.65 | 0.00 | 87.36 | 4.70 | 2.66 | 2.34 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.05 | -0.06 | -0.01 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.05 | -0.06 | -0.01 | 0.00 |
| Cash from Financing Activities | 6.50 | 6.58 | -25.03 | -10.71 | -13.56 | 87.31 | 4.64 | 2.73 | 2.34 |
| Exchange Rate Effect | 0.00 | 0.00 | -0.00 | -0.00 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 |
| Net Change in Cash | 4.56 | 3.43 | -35.01 | -17.86 | -17.36 | 83.20 | 1.31 | 0.38 | -0.54 |
| Free Cash Flow | -3.94 | -5.15 | -2.98 | -2.15 | -3.79 | -4.12 | -3.33 | -2.34 | -2.88 |
| Preferred Dividends (Cash Flow) | - | -0.25 | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 30.51 | 37.08 | 20.54 | 15.61 | 13.44 | 15.54 |
| Short Term Receivables | 0.43 | 0.24 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.03 | 0.10 | 0.16 | 7.42 | 5.67 | 6.84 |
| Total Current Assets | 30.97 | 37.42 | 20.70 | 23.02 | 19.11 | 22.38 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Investments and Advances | 5.73 | 9.32 | 33.62 | 31.40 | 24.45 | 31.24 |
| Intangible Assets | - | 0.00 | 1.55 | 1.55 | 1.55 | 1.55 |
| Other Assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Total Assets | 36.71 | 46.75 | 55.87 | 55.98 | 45.11 | 55.17 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 0.39 | 0.27 | 1.20 | 1.02 | 0.47 | 0.40 |
| Other Current Liabilities | 0.38 | 0.56 | 0.48 | 0.56 | 0.60 | 2.52 |
| Total Current Liabilities | 0.77 | 0.83 | 1.68 | 1.58 | 1.06 | 2.91 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 6.13 | 10.95 | 14.79 | 17.84 | 0.46 | 0.36 |
| Total Liabilities | 6.90 | 11.77 | 16.47 | 19.42 | 1.52 | 3.28 |
| Non-Equity Reserves | 0.42 | 0.42 | 0.42 | 0.42 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 1.89 | 1.27 | 0.87 | 0.90 | 0.00 | 0.00 |
| Common Equity | 27.51 | 33.29 | 38.11 | 35.24 | 43.59 | 51.89 |
| Total Shareholders Equity | 29.40 | 34.56 | 38.99 | 36.14 | 43.59 | 51.89 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 29.40 | 34.56 | 38.99 | 36.14 | 43.59 | 51.89 |
| Total Liabilities & Stockholders Equity | 36.71 | 46.75 | 55.87 | 55.98 | 45.11 | 55.17 |
| Book Value Per Share | 2.56 | 3.10 | 3.55 | 5.18 | 6.41 | 7.64 |
| Tangible Book Value Per Share | 2.56 | 3.10 | 3.41 | 4.96 | 6.19 | 7.41 |
| Full-Time Employees | - | 2 | - | - | - | 2 |
| Price to Book Ratio | 0.16 | 0.20 | 0.16 | 0.14 | 0.17 | 0.21 |
| Return on Assets | -39.47 | -38.12 | -6.58 | -12.74 | -1.95 | 53.28 |
| Return on Equity | -44.24 | -44.94 | -8.28 | -17.78 | -2.33 | 67.08 |
| Return on Invested Capital | -17.28 | -12.71 | 1.92 | -20.53 | -19.18 | 22.64 |
| Quick Ratio | 40.30 | 45.28 | 12.33 | 14.60 | 18.01 | 7.68 |
| Current Ratio | 40.30 | 45.28 | 12.33 | 14.60 | 18.01 | 7.68 |
Cash flow, quarterly
| Metric | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|
| Net Income | -5.08 | -11.96 | 0.75 | -7.42 | -8.36 | 11.75 |
| Other Funds (Non Cash) | 4.48 | 11.65 | -1.51 | 6.31 | 7.32 | -14.05 |
| Funds from Operations | -0.60 | -0.31 | -0.77 | -1.11 | -1.04 | -2.30 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.18 | -1.08 | -0.02 | 0.13 | -0.95 | 1.26 |
| Cash from Operating Activities | -0.78 | -1.39 | -0.79 | -0.98 | -1.99 | -1.04 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 5.00 | -3.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | -3.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 5.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 5.00 | -3.00 | 0.00 | 0.00 |
| Cash Dividends Paid | -0.08 | -0.08 | -0.10 | -0.06 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | -0.08 | -0.08 | -0.10 | -0.06 | 0.00 | - |
| Change in Capital Stock | 0.00 | -0.09 | 0.65 | 6.27 | 0.00 | -0.17 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | -0.40 | 0.00 | 0.00 | -0.17 |
| Sale of Common Pref Stock | 0.00 | -0.09 | 1.05 | 6.27 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -0.08 | -0.17 | 0.54 | 6.21 | 0.00 | -0.17 |
| Exchange Rate Effect | -0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Net Change in Cash | -0.86 | -1.56 | 4.76 | 2.23 | -1.99 | -1.21 |
| Free Cash Flow | -0.78 | -1.39 | -0.79 | -0.98 | -1.99 | -1.04 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.50% | 0.1M | 10.1M | 185.45K |
| 2026-10-15 | 0.70% | 0.1M | 10.1M | 204.32K |
| 2026-09-30 | 1.33% | 0.1M | 10.1M | 202.00K |
| 2026-09-15 | 0.70% | 0.1M | 10.1M | 128.33K |
| 2026-08-31 | 0.79% | 0.1M | 10.1M | 110.64K |
| 2026-08-14 | 2.07% | 0.2M | 10.1M | 138.83K |
| 2026-07-31 | 2.90% | 0.3M | 10.1M | 183.08K |
| 2026-07-15 | 3.20% | 0.3M | 10.1M | 174.12K |
| 2026-06-30 | 3.24% | 0.3M | 10.1M | 180.98K |
| 2026-06-15 | 3.48% | 0.4M | 10.1M | 199.48K |
| 2026-05-29 | 3.74% | 0.4M | 10.1M | 198.16K |
| 2026-05-15 | 4.67% | 0.5M | 10.1M | 178.60K |
| 2026-04-30 | 1.02% | 0.1M | 10.1M | 143.03K |
| 2026-04-15 | 0.84% | 0.1M | 10.1M | 182.53K |
| 2026-03-31 | 0.98% | 0.1M | 9.9M | 237.72K |
| 2026-03-13 | 0.98% | 0.1M | 9.9M | 282.87K |
| 2026-02-27 | 1.14% | 0.1M | 9.4M | 2.59M |
| 2026-02-13 | 1.50% | 0.1M | 9.4M | 3.54M |
| 2026-01-30 | 2.07% | 0.2M | 8.7M | 3.51M |
| 2026-01-15 | 2.04% | 0.2M | 8.7M | 3.41M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 0.00 | 3.80 | 0.00 | 0.000 | 0.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 5.00 | 0.00 | 3.80 | 0.00 | 0.000 | 0.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| call | 7.50 | 0.00 | 3.80 | 0.00 | 0.000 | 0.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| put | 2.50 | 0.00 | 4.70 | 2.20 | 0.000 | 4.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| put | 5.00 | 2.20 | 7.00 | 4.60 | 0.000 | 7.00 | 0.00 | 0.000 | 0.000 | 0.000 |
| put | 7.50 | 4.70 | 9.50 | 7.20 | 0.000 | 0.00 | 0.00 | 0.000 | 0.000 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-10-16 | 8-K | Current report | 2026-10-14 | SEC |
| 2026-09-14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-07-31 | SEC |
| 2026-07-29 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2026-04-30 | SEC |
| 2026-07-17 | 4/A | 2026-03-31 | SEC | |
| 2026-07-17 | 4/A | 2026-03-31 | SEC | |
| 2026-07-17 | 4/A | 2026-03-31 | SEC | |
| 2026-07-17 | 4/A | 2026-03-31 | SEC | |
| 2026-04-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-31 | SEC |
| 2026-04-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-31 | SEC |
| 2026-04-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-31 | SEC |
| 2026-04-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-31 | SEC |
| 2026-04-02 | 8-K | Current report | 2026-03-30 | SEC |
| 2026-03-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-17 | SEC |
| 2026-03-18 | SCHEDULE 13G | SEC | ||
| 2026-03-17 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-01-31 | SEC |
| 2026-03-09 | ARS | Annual report to security holders. | 2025-04-30 | SEC |
| 2026-03-09 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-03-30 | SEC |
| 2026-02-27 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-03-30 | SEC |
| 2026-02-13 | SCHEDULE 13G/A | SEC | ||
| 2026-01-07 | 4 | Statement of changes in beneficial ownership of securities | 2026-01-05 | SEC |
| 2026-01-07 | 4 | Statement of changes in beneficial ownership of securities | 2026-01-05 | SEC |
| 2025-12-18 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2025-10-31 | SEC |
| 2025-12-15 | NT 10-Q | 2025-10-31 | SEC | |
| 2025-12-12 | 4 | Statement of changes in beneficial ownership of securities | 2025-04-25 | SEC |
| 2025-12-12 | 4 | Statement of changes in beneficial ownership of securities | 2025-04-25 | SEC |
| 2025-12-12 | 4 | Statement of changes in beneficial ownership of securities | 2025-12-12 | SEC |
| 2025-12-12 | 4 | Statement of changes in beneficial ownership of securities | 2025-04-25 | SEC |
| 2025-12-12 | 4 | Statement of changes in beneficial ownership of securities | 2025-04-25 | SEC |
| 2025-12-05 | 8-K | Current report | 2025-12-01 | SEC |
| 2025-11-18 | 4 | Statement of changes in beneficial ownership of securities | 2025-09-04 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 128.71K | 6 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| CITADEL ADVISORS LLC | 2.64% |
| GEODE CAPITAL MANAGEMENT, LLC | 1.15% |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.53% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.42% |
| RENAISSANCE TECHNOLOGIES LLC | 0.35% |
| XTX Topco Ltd | 0.32% |
| NORTHERN TRUST CORP | 0.30% |
| JANE STREET GROUP, LLC | 0.28% |
| StoneX Group Inc. | 0.28% |
| Schonfeld Strategic Advisors LLC | 0.25% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Extended Market Index Fund | 0.54% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.53% |
| Fidelity Nasdaq Composite Index Fund | 0.16% |
| Fidelity Total Market Index Fund | 0.14% |
| Fidelity Series Total Market Index Fund | 0.12% |
OakChart. PMCB. Cached 15 minutes.
Some panels did not load: ratings.